176 related articles for article (PubMed ID: 36463765)
21. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Mason BJ
Eur Neuropsychopharmacol; 2003 Dec; 13(6):469-75. PubMed ID: 14636963
[TBL] [Abstract][Full Text] [Related]
22. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Klemperer EM; Hughes JR; Naud S
Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
24. Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
Scherbaum N; Holzbach R; Stammen G; Kirchof U; Bonnet U
Pharmacopsychiatry; 2020 Jan; 53(1):37-39. PubMed ID: 31132796
[TBL] [Abstract][Full Text] [Related]
25. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M; Chick J
Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
[TBL] [Abstract][Full Text] [Related]
26. Group management of pharmacotherapy for alcohol dependence: feasibility and impact on adoption.
Robinson S; Bowe T; Harris AH
J Subst Abuse Treat; 2013; 45(5):475-7. PubMed ID: 23932227
[TBL] [Abstract][Full Text] [Related]
27. Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Votaw VR; Mann K; Kranzler HR; Roos CR; Nakovics H; Witkiewitz K
Drug Alcohol Depend; 2022 Mar; 232():109257. PubMed ID: 35042096
[TBL] [Abstract][Full Text] [Related]
28. Rates of prescription orders for United States active duty service members diagnosed with alcohol use disorder.
Peters ZJ; Kincaid MW; Greenberg JG; Quah RF; Curry JC
Subst Abus; 2021; 42(4):638-645. PubMed ID: 32870103
[No Abstract] [Full Text] [Related]
29. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Wiercigroch D; Sheikh H; Hulme J
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):4. PubMed ID: 31931831
[TBL] [Abstract][Full Text] [Related]
30. Advances in Pharmacotherapy Development: Human Clinical Studies.
Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
[TBL] [Abstract][Full Text] [Related]
31. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
[No Abstract] [Full Text] [Related]
32. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
33. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India.
Basu D; Jhirwal OP; Mattoo SK
Am J Addict; 2005; 14(4):381-95. PubMed ID: 16188718
[TBL] [Abstract][Full Text] [Related]
34. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
35. Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
Morley KC; Logge W; Pearson SA; Baillie A; Haber PS
J Subst Abuse Treat; 2017 Mar; 74():23-25. PubMed ID: 28132696
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacotherapy of alcohol withdrawal: update and new developments].
Soyka M; Rösner S
Nervenarzt; 2021 Jan; 92(1):57-65. PubMed ID: 32696076
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
38. Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Doggrell SA
Expert Opin Pharmacother; 2006 Oct; 7(15):2169-73. PubMed ID: 17020440
[TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
McPheeters M; O'Connor EA; Riley S; Kennedy SM; Voisin C; Kuznacic K; Coffey CP; Edlund MD; Bobashev G; Jonas DE
JAMA; 2023 Nov; 330(17):1653-1665. PubMed ID: 37934220
[TBL] [Abstract][Full Text] [Related]
40. The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
Litten RZ; Castle IJ; Falk D; Ryan M; Fertig J; Chen CM; Yi HY
Alcohol Clin Exp Res; 2013 Dec; 37(12):2128-37. PubMed ID: 23889231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
